Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.

Human vaccines - 1 Jan 2000

Harris Shannon L, Zhu Duzhang, Murphy Ellen, McNeil Lisa K, Wang Xin, Mayer Leonard W, Harrison Lee H, Jansen Kathrin U, Anderson Annaliesa S

Abstract excerpt

A bivalent factor H binding protein (fHBP) vaccine for the prevention of disease caused by Neisseria meningitidis serogroup B is currently in clinical development. Since fHBP is also expressed by other meningococcal serogroups, anti-fHBP antibodies may have bactericidal activity against meningoco...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bacterial
Share to Antigens, Bacterial
Share to Blood Bactericidal Activity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement System Proteins

Share to Macaca fascicularis

Share to Meningococcal Infections

Share to Meningococcal Vaccines

Share to Rabbits

Source

Open in PubMed Open full text

Identifiers

PMID: 21245657
DOI: 10.4161/hv.7.0.14564
PMCID: PMC3367671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21245657-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.PMID 21245657Read ↗

Meningococcal serogroup B vaccines: Estimating breadth of coverageSemantic proximity Read ↗

Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal DiseaseSemantic proximity Read ↗

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis.Semantic proximity Read ↗

The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococciSemantic proximity Read ↗

Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine DevelopmentSemantic proximity Read ↗

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic VaccineSemantic proximity Read ↗

Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigenSemantic proximity Read ↗

Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.Semantic proximity Read ↗

<i>Neisseria meningitidis</i>serogroup B bivalent factor H binding protein vaccineSemantic proximity Read ↗

Meningococcal factor H binding protein as immune evasion factor and vaccine antigenSemantic proximity Read ↗

Potential impact of the bivalent rLP2086 vaccine on<i>Neisseria meningitidis</i>carriage and invasive serogroup B diseaseSemantic proximity Read ↗

Factor H binding protein (FHbp): An evaluation of genotypic diversity across Neisseria meningitidis serogroups.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.